Moderna (NASDAQ:MRNA) surge puts stock above most analyst targets ahead of FDA review
Moderna, Inc. heads into Monday’s U.S. session with its shares now outpacing most analyst targets, leaving the main story a stock issue instead of a scientific one. The stock traded at $67.63 in premarket at 7:01 a.m. EDT, up 0.54%, after jumping 12.59% to $67.27 on Friday. Volume hit 14.46 million shares Friday, 203% of the 65-day average. Moderna was one of the few large healthcare plays to rally Friday, as the rest of the market drifted lower. The S&P 500 slipped 0.05% and the Nasdaq lost 0.24%, according to Reuters, but Moderna shares shot up nearly 13% after its investor event. Early Monday, U.S. futures traded stronger, with S&P 500 E-minis up 0.68% and Nasdaq 100 E-minis up 1.02%